Ethnic sensitive or molecular sensitive beyond all regions being equal in multiregional clinical trials

Journal of Biopharmaceutical Statistics

Volumn 22, Issue 5, 2012, Pages 879-893

  Wang, Sue Jane ^a   James Hung, H M ^b  

^a Office of Biostatistics   (United States)

^b Division of Biometrics i   (United States)

Author keywords

Bayesian credible interval; Ethnic sensitive; Molecular sensitive; Region driven

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; CAPTOPRIL; CLOPIDOGREL; ERLOTINIB; IRBESARTAN; LOSARTAN; TAMOXIFEN;

ACCURACY; ACUTE CORONARY SYNDROME; ARTICLE; BAYESIAN LEARNING; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; ETHNIC DIFFERENCE; EUROPE; GENETIC VARIABILITY; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL PRACTICE; MOLECULAR MECHANICS; MORTALITY; MULTIREGIONAL CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SOUTH AND CENTRAL AMERICA;

ALGORITHMS; BAYES THEOREM; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DRUG THERAPY; ENDPOINT DETERMINATION; ETHNIC GROUPS; GENETIC VARIATION; HUMANS; MULTICENTER STUDIES AS TOPIC; PHARMACOGENETICS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 84866271129     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2012.701576     Document Type: Article

References (30)

1. Brenner, B. M., Cooper, M. E., Zeeuw, D. D., Keane, W. F., Mitch, W. E., Parving, H. H., Remuzzi, G., Snapinn, S. M., Zhang, Z., Shahinfar, S. (2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine 345 (12): 861-869.
2. Chan, J. C. N., Wat, N. M. S., So, W. Y., Lam, K. S. L., Chua, C. T., Wong, K. S., Morad, Z., Dickson, T. Z., Hille, D., Zhang, Z., Cooper, M. E., Shahinfar, S., Brenner, B. M., Kurokawa, K. (2004). Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. Diabetes Care 27 (4): 874-879. (Pubitemid 38420207)
3. Chen, Y. F., Wang, S. J., Khin, N. A., Hung, H. M. J., Laughren, T. P. (2010). Trial design issues and treatment effect modeling in mult-regional schizophrenia trials. Pharmaceutical Statistics 9 (3): 217-219.
4. Collet, J. P., Hulot, J. S., Pena, A., Villard, E., Esteve, J. B., Silvain, J., Payot, L., Brugier, D., Cayla, G., Bygui, F., Bensimon, G., Funck-Brentano, C., Montalescot, G. (2009). Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 373: 309-317.
5. George, R. B., Light, R. W., Matthay, R. A., eds. (2005). Clinical pulmonary function testing, exercise testing, and disability evaluation. In: Chest Medicine: Essentials of Pulmonary and Critical Care Medicine., 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, pp. 90-112.
6. Getz, K. A. (2007). Global clinical trials activity in the details. Applied Clinical Trials, September 1. Accessed November 22, 2010. http://appliedclinicaltrialsonline. findpharma.com/appliedclinicaltrials/ article/articleDetail.jsp?id=453243
7. Glickman, S. W., McHutchison, J. G., Peterson, E. D., Cairns, C. B., Harrington, R. A., Califf, R. M., Schulman, K. A. (2009). Ethical and scientific implications of the globalization of clinical research. New England Journal of Medicine 360 (8): 816-823.
8. Goetz, M. P., Knox, S. K., Suman, V. J., Rae, J. M., Safgren, L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Weinshilboum, R. M., Fritcher, E. G., Nibbe, A. M., Desta, Z., Nguyen, A., Flockhart, D. A., Perez, E. A., Ingle, J. N. (2007). The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Research and Treatment 101: 113-121. (Pubitemid 47555336)
9. Goldstein, D. B., Kate, S. K., Sisodiya, S. M. (2003). Pharmacogenetics goes genomics. Nature Reviews Genetics 4: 937-947.
10. Hung, H. M. J., Wang, S. J., O'Neill, R. T. (2010). Consideration of regional difference in design and analysis of multi-regional trials. Pharmaceutical Statistics 9: 173-178.
11. International Conference on Harmonization. (1998). Ethnic Factors in the Acceptability of Foreign Clinical Data (ICH E-5). CPMP/ICH/289/95. London, UK: European Agency for the Evaluation of Medicinal Products.
12. International Conference on Harmonization. (2006). International Conference on Harmonization Guideline E5. Questions & answers for the ICH E-5 guidance on ethnic factor in the acceptability of foreign data. http://www.ich. org/cache/compo/276-254-1.html
13. Kohasaka, S., Kimura, T., Goto, M., Lee, V. V., Elayda, M., Furukawa, Y., Fukushima, M., Komeda, M., Sakata, R., Willerson, J. T., Wilson, J. M., Kita, T. (2010). Difference in patient profiles and outcomes in Japanese versus American patients undergoing coronary revascularization (Collaborative study by CREDO-Kyoto and Texas heart institute research database). American Journal of Cardiology 105: 1698-1704.
14. Lauritsen, B. J., Madsen, H. (1974). A multinational double-blind trial with a new antidepressant maprotiline (Ludiomil) and amitriptyline. Acta Psychiatrica Scandinavica 50 (2): 192-201.
15. Lewis, E. J., Hunsicker, L. G., Bain, R., Rohde, R. (1993). The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. New England Journal of Medicine 329: 1456-1462. (Pubitemid 23335891)
16. Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., Raz, I. (2001). Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine 345 (2): 851-860.
17. Luo, X., Shih, W., Ouyang, P., DeLap, B. (2010). An optimal adaptive design to address local regulations in global clinical trials. Pharmaceutical Statistics 9 (3): 179-189.
18. Mega, J. L., Close, S. L., et al. (2009). Cytochrome P-450 polymorphisms and response to clopidogrel. New England Journal of Medicine 360: 354-362.
19. Mehta, S. R., Yusuf, S. (2000). The clopidogrel in unstable angina to prevent recurrent events (CURE) trial programme: Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. European Heart Journal 21 (24): 2033-2041. (Pubitemid 32006217)
20. Miller, A. (1986). A pulmonary function tests in clinical and occupational disease. Philadelphia, PA: Grune & Stratton.
21. Pare, G., Mehta, S. R., Yusuf, S., Anand, S. S., Connolly, S. J., Hirsh, J., Simonsen, K., Bhatt, D. L., Fox, K. A. A., Eikelboom, J. W. (2010). Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. New England Journal of Medicine. doi: 10.1056/NEJMoa1008410
22. Shuldiner, A. R., O'Connell, J. R., Bliden, K. P., Gandhi, A., Ryan, K., Horenstein, R. B., Damcott, C. M., Pakyz, R., Tantry, U. S., Gibson, Q., Pollin, T. I., Post, W., Parsa, A., Mitchell, B. E. D., Faraday, N., Herzog, W., Gurbel, P. A. (2009). Association of cytochrome P450 2C19 genotyep with the antiplatelet effect and clinical efficacy of clopidogrel therapy. Journal of the American Medical Association 302: 849-857.
23. Tarceva. (2004). Tarceva (erlotinib) labeling package insert. http://www. tarceva.com/tarceva/patient/PI.jsp
24. Wang, S. J. (2007). Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI. Pharmaceutical Statistics 6 (4): 283-296. doi: 10.1002/pst316
25. Wang, S. J. (2009). Bridging studies versus pre-specified regions nested in global trials. Special issue on Partnership in Harmonization for Global Drug Development in Asia/Pacific. Drug Information Journal 43: 27-34.
26. Wang, S. J., Cohen, N., Katz, D. A., Ruano, G., Shaw, P., Spear, B. (2006). Retrospective validation of genomic biomarkersWhat are the questions, challenges and strategies for developing useful relationships to clinical outcomesWorkshop summary. Pharmacogenomics Journal 6: 82-88.
27. Wang, S. J., O'Neill, R. T., Hung, H. M.J. (2007). Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 6: 227-244. (Pubitemid 47455262)
28. Wang, S. J., Hung, H. M. J., O'Neill, R. T. (2009). Adaptive patient enrichment designs in therapeutic trials. Biometrical Journal 51 (2): 358-374.
29. Wang, S. J., O'Neill, R. T., Hung, H. M.J. (2010). Some statistical considerations in evaluating pharmacogenomics confirmatory clinical trials. Clinical Trials 7: 525-536.
30. Wegman, P., Vainikka, L., Stal, O., Nordenskjold, B., Skoog, L., Rutqvist, L. E., Wingren, S. (2005). Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Research 7: R284-R290.